Phase 1 study of NB003, a broad-spectrum KIT/PDGFRα inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST).

被引：0
|
作者：
Li, Jian
Chi, Ping
Kang, Yoon-Koo
Cao, Hui
George, Suzanne
Zhang, Jun
Zhang, Jian
Hu, Kang
Zhang, Lijia
Xu, Yanhua
机构：
[1] Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst,Minist Educ, Lab Carcinogenesis & Translat Res,Dept Gastrointe, Beijing, Peoples R China
[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[3] Univ Ulsan, Dept Oncol, Asan Med Ctr, Seoul, South Korea
[4] Shanghai Jiao Tong Univ, Renji Hosp, Dept Gastrointestinal Surg, Sch Med, Shanghai, Peoples R China
[5] Dana Farber Canc Inst, Dept Med Oncol, Sarcoma Ctr, Boston, MA USA
[6] Chongqing Med Univ, Dept Gastroenterol, Affiliated Hosp 1, Chongqing, Peoples R China
[7] Fudan Univ, Dept Med Oncol, Phase 1 Clin Trial Ctr, Shanghai Canc Hosp, Shanghai, Peoples R China
[8] Ningbo Newbay Technol Dev Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11518
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate
    Sawaki, Akira
    Yamada, Yasuhide
    Komatsu, Yoshito
    Kanda, Tatsuo
    Doi, Toshihiko
    Koseki, Masato
    Baba, Hideo
    Sun, Yu-Nien
    Murakami, Koji
    Nishida, Toshirou
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (05) : 961 - 967
  • [42] A Randomized Phase II Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Patients with Advanced Gastrointestinal Stromal Tumors
    Singh, Arun S.
    Hecht, J. Randolph
    Rosen, Lee
    Wainberg, Zev A.
    Wang, Xiaoyan
    Douek, Michael
    Hagopian, Anahis
    Andes, Rachel
    Sauer, Lauren
    Brackert, Sandra R.
    Chow, Warren
    DeMatteo, Ronald
    Eilber, Fritz Christian
    Glaspy, John A.
    Chmielowski, Bartosz
    CLINICAL CANCER RESEARCH, 2022, 28 (01) : 84 - 94
  • [43] Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate
    Akira Sawaki
    Yasuhide Yamada
    Yoshito Komatsu
    Tatsuo Kanda
    Toshihiko Doi
    Masato Koseki
    Hideo Baba
    Yu-Nien Sun
    Koji Murakami
    Toshirou Nishida
    Cancer Chemotherapy and Pharmacology, 2010, 65 : 961 - 967
  • [44] A phase II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with untreated advanced gastrointestinal stromal tumor (GIST).
    Chi, Ping
    Qin, Li-Xuan
    Kelly, Ciara Marie
    D'Angelo, Sandra P.
    Dickson, Mark Andrew
    Gounder, Mrinal M.
    Keohan, Mary Louise
    Movva, Sujana
    Nacev, Benjamin
    Crago, Aimee Marie
    Yoon, Sam S.
    Ulaner, Gary A.
    Martindale, Moriah
    Condy, Mercedes M.
    Biniakewitz, Haley Phelan Matthew
    Singer, Samuel
    Hwang, Sinchun
    Antonescu, Cristina R.
    Tap, William D.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [45] A phase Ib/II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST)
    Chi, Ping
    Qin, Li-Xuan
    D'Angelo, Sandra P.
    Dickson, Mark Andrew
    Gounder, Mrinal M.
    Keohan, Mary Louise
    Shoushtari, Alexander Noor
    Condy, Mercedes M.
    Konen, Theresa
    Fruauff, Alana
    DeMatteo, Ronald P.
    Singer, Samuel
    Hwang, Sinchun
    Antonescu, Cristina R.
    Tap, William D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] Dynamics of KIT exon 11 mutations in cell free plasma DNA of patients treated for advanced gastrointestinal stromal tumors: Results from the Dutch GIST bio-databank
    Boonstra, Pieter A.
    ter Elst, Arja
    Tibbesma, Marco
    Mathijssen, Ron H.
    Atrafi, Florence
    van Coevorden, Frits
    Farag, Sheima
    Steeghs, Neeltje
    Desar, Ingrid M.
    Van der Graaf, Winette T.
    Gelderblom, Hans
    van Etten, Boudewijn
    Overbosch, Jelle
    Suurmeijer, Albert J.
    Gietema, Jourik A.
    Schuuring, Ed
    Reyners, Anna K.
    CANCER RESEARCH, 2017, 77
  • [47] A phase 1, multicenter, open-label, first-in-human study of DS-6157a in patients (pts) with advanced gastrointestinal stromal tumor (GIST).
    George, Suzanne
    Heinrich, Michael C.
    Somaiah, Neeta
    Van Tine, Brian Andrew
    McLeod, Robert
    Laadem, Abderrahmane
    Cheng, Ben
    Nishioka, Satoshi
    Kundu, Madan Gopal
    Qian, Xiaozhong
    Lau, Yvonne Y.
    Tran, Brittany
    Kumar, Prasanna
    Dosunmu, Ololade
    Shi, Julia
    Naito, Yoichi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [48] A phase I study of nilotinib alone and in combination with imatinib (IM) in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST) - Study update
    Von Mehren, M.
    Reichardt, P.
    Casali, P. G.
    Blay, J.
    Debiec-Rychter, M.
    Dumez, H.
    Cheung, W.
    Feifel, B.
    Veronese, M.
    Demetri, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [49] Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors
    Kawazoe, Akihito
    Kuboki, Yasutoshi
    Bando, Hideaki
    Fukuoka, Shota
    Kojima, Takashi
    Naito, Yoichi
    Iino, Shuichi
    Yodo, Yasuhide
    Doi, Toshihiko
    Shitara, Kohei
    Yoshino, Takayuki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (05) : 855 - 862
  • [50] Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors
    Akihito Kawazoe
    Yasutoshi Kuboki
    Hideaki Bando
    Shota Fukuoka
    Takashi Kojima
    Yoichi Naito
    Shuichi Iino
    Yasuhide Yodo
    Toshihiko Doi
    Kohei Shitara
    Takayuki Yoshino
    Cancer Chemotherapy and Pharmacology, 2020, 85 : 855 - 862
12345